Press release
23 July 2026

Kringle Pharma Highlights Publication of NASCIC Perspective Paper in *Spinal Cord*

Osaka, Japan – Kringle Pharma, Inc. (Tokyo Stock Exchange Growth: 4884, "KRINGLE"), a late-stage clinical biopharmaceutical company developing innovative therapies for rare and difficult-to-treat diseases, today announced the publication in *Spinal Cord*, the official journal of the International Spinal Cord Society (ISCoS), of a paper by the North American Spinal Cord Injury Consortium (NASCIC) exploring what constitutes a "clinically meaningful improvement" for individuals with traumatic cervical spinal cord injury (SCI) from a participant-centered perspective. The findings were supported by KRINGLE as part of its commitment to advancing patient-centered research and improving outcomes for people linving with SCI.

The paper is based on interviews conducted by NASCIC with individuals living with traumatic cervical SCI in the United States and Canada to better understand their recovery priorities and the real-world impact of functional improvements on daily life. The findings identified improvements in hand and arm function, bladder and bowel function, and trunk stability among the highest-priority recovery goals from the patient perspective. Importantly, the paper demonstrates that even small functional gains can translate into meaningful benefits, including greater independence, reduced caregiver burden, and improved quality of life (QOL). The publication further highlintes the need to evaluate outcomes that truly matter to individuals with SCI and that may not be fully captured by conventional clinical assessment measures. By highlighting the patient voice, this paper provides important insight for the development of future patient-centered outcome measures and clinical trial designs that accurately reflect the real-worl needs and priorities of individuals living with SCI.

KRINGLE is currently advancing the development of oremepermin alfa, a recombinant human hepatocyte growth factor, for acute SCI. KRINGLE remains committed to promoting research and development that incorporates the perspectives of individuals living with SCI, with the goal of delivering innovative therapies that address significant unmet medical needs. KRINGLE is unyielding in our pursuit of life-changing treatments for acute SCI. By uniting hand-in-hand with patients, clinicians, advocacy groups, and researchers, we are in this for the long haul, maintaining an unwavering resolve to push these critical effots forward without compromise– and we will never give up on our promise to deliver better outcomes.

[Publication Information]
Title: Redefining Clinically Meaningful Improvement in Traumatic Cervical Spinal Cord Injury: A Patient-Centered Perspective From Community Feedback Sessions
Authors: Ian Burkhart, Marco Sorani, Gabriela Ocampo
Journal: *Spinal Cord*
DOI: https://doi.org/10.1038/s41393-026-01244-8
URL: https://www.nature.com/articles/s41393-026-01244-8 (Open access)

About North American Spinal Cord Injury Consortium (NASCIC)
The North American Spinal Cord Injury Consortium (NASCIC) brings together organizations, individuals, and groups across the spinal cord injury community to advance research, care, cure, and policy. Through collaborative projects and community engagement, NASCIC works to improve outcomes for people living with spinal cord injury, their families, and their communities.

About Hepatocyte Growth Factor (HGF)

HGF, initially identified as an endogenous mitogen for mature hepatocytes, has demonstrated a wide array of biological functions, including mitogenic, motogenic, anti-apoptotic, morphogenic, anti-fibrotic, and angiogenic activities. It is crucial for the regeneration and protection of various organs. Importantly, HGF has shown neurotrophic effects and has been validated in animal models for its therapeutic potential in spinal cord injuries, as demonstrated by research conducted by Professors Hideyuki Okano and Masaya Nakamura at Keio University School of Medicine. Enthusiasm for HGF as a groundbreaking therapeutic agent for spinal cord injury continues to grow.

Meanwhile, a research team led by Professor Shigeru Hirano in the Department of Otolaryngology and Head and Neck Surgery at Kyoto Prefectural University of Medicine has investigated the anti-fibrotic effects of HGF and demonstrated its effectiveness in treating vocal cord scarring. HGF is also emerging as a promising therapeutic option for a range of fibrotic diseases.

About Kringle Pharma, Inc. https://www.kringle-pharma.com/en/

Founded in December 2001, Kringle Pharma is a late-stage clinical biopharmaceutical company focused on developing innovative biologics based on HGF. Oremepermin alfa is currently in Phase 3 in Japan for the treatment of acute spinal cord injury and vocal cord scarring. Kringle's mission is to improve societal and global healthcare by advancing the research, development, and commercialization of HGF-based therapies for patients with incurable diseases. To accelerate the international development of oremepermin alfa, Kringle Pharma USA, Inc. was established in November 2025 as a U.S. subsidiary.

Business Development, Investor, and Media Contact:

Matt Vogelhuber
President, US Head of Operations
Kringle Pharma USA, Inc.
Phone: 770-570-0641
Email: mvogelhuber@kringle-pharma.com

Kazuki Kaneshiro
Director, Corporate Strategy Office
Kringle Pharma, Inc.
Phone: +81-6-7653-6728
Email: kpinfo@kringle-pharma.com